One of the #antibodydrugconjugates at the heart of #Pfizer's $43 billion acquisition of Seagen three years ago has failed a keenly anticipated phase 3 trial in #lungcancer.
One of the antibody-drug conjugates at the heart of Pfizer's $43bn acquisition of Seagen three years ago has failed a phase 3 lung cancer trial.
